SCHEMBL20766526

SCHEMBL20766526

CNS(=O)(=O)c1ccc(NC2CCCCC2)c(-c2cn(C)cn2)c1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
YAP1 P46937 2/20 0.57
TEAD1 P28347 1/20 0.57
BRD4 O60885 6/20 0.45
SYK P43405 2/20 0.41
ALOX15 P16050 2/20 0.39
S1PR1 P21453 1/20 0.38
S1PR3 Q99500 1/20 0.38
WNK1 Q9H4A3 2/20 0.38
LMNA P02545 2/20 0.36
TAS2R14 Q9NYV8 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
GPR55 Q9Y2T6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20767153 0.87 YAP1 (0.43) YAP1TEAD1BRD4SYKALOX15
SCHEMBL22635634 0.87 TEAD1 (0.60) YAP1TEAD1BRD4SYK
SCHEMBL20779718 0.87 TEAD1 (0.60) YAP1TEAD1BRD4SYK
SCHEMBL29648372 0.87 TEAD1 (0.60) YAP1TEAD1BRD4SYK
SCHEMBL20779716 0.87 TEAD1 (0.60) YAP1TEAD1BRD4SYK
SCHEMBL20766444 0.86 YAP1 (0.43) YAP1TEAD1BRD4SYKALOX15
SCHEMBL20767465 0.86 YAP1 (0.43) YAP1TEAD1BRD4SYKALOX15
SCHEMBL24496264 0.84 TEAD1 (0.56) YAP1TEAD1BRD4S1PR1S1PR3
SCHEMBL20767361 0.84 BRD4 (0.43) YAP1TEAD1BRD4SYKALOX15
SCHEMBL20766974 0.83 BRD4 (0.45) YAP1TEAD1BRD4SYKALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 US disclosed
CN-111542315-B Benzosulfonyl compounds 维瓦斯治疗公司 2023-05-12 CN disclosed
EP-3691623-B1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS INC (US) 2022-10-05 EP disclosed
US-11192865-B2 Benzosulfonyl compounds VIVACE THERAPEUTICS, INC. (US) 2021-12-07 US disclosed
US-11192865-B2 Benzosulfonyl compounds VIVACE THERAPEUTICS, INC. (US) 2021-12-07 US disclosed
US-20200354325-A1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS, INC. 2020-11-12 US disclosed
US-20200354325-A1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS, INC. 2020-11-12 US disclosed
CN-111542315-A Benzosulfonyl compounds 维瓦斯治疗公司 2020-08-14 CN disclosed
EP-3691623-A1 BENZOSULFONYL COMPOUNDS Vivace Therapeutics, Inc. (US) 2020-08-12 EP disclosed
WO-2019040380-A1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS, INC. (US) 2019-02-28 WO disclosed
WO-2019040380-A1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS, INC. (US) 2019-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11192865-B2 Benzosulfonyl compounds YAP1, TEAD2, TEAD1 YAP1 1/4885TEAD1 3/4885BRD4 7/4885
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF TEAD1, TEAD4, TEAD2 YAP1 9/4885TEAD1 1/4885BRD4 328/4885
US-20200354325-A1 BENZOSULFONYL COMPOUNDS YAP1, TEAD2, TEAD1 YAP1 1/4885TEAD1 3/4885BRD4 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.